Home › Anal Cancer › Ohio › Cleveland
Anal Cancer clinical trials in Cleveland, OH
3 studies for Anal Cancer are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Recruiting
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RecruitingPhase 1
- University Hospitals Cleveland Medical Center, Cleveland
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
RecruitingPhase 2
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Cent, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Center, Cleveland
About Anal Cancer
Anal cancer is rare. HPV is one of the most common causes. Find out more about anal cancer symptoms, diagnosis, and treatment.
More about Anal Cancer on MedlinePlus
Anal Cancer trials in other cities
- Houston, TX6 studies
- Nashville, TN5 studies
- Los Angeles, CA5 studies
- San Francisco, CA4 studies
- New York City, NY4 studies
- Edison, NJ4 studies
- Chicago, IL3 studies
- Atlanta, GA3 studies
Other studies in Cleveland
- Non-Small Cell Lung Cancer43 studies
- Cancer (all types)36 studies
- Breast Cancer35 studies
- Prostate Cancer34 studies
- Heart Failure33 studies
- Ovarian Cancer30 studies
- Metastatic Cancer30 studies
- Lung Cancer26 studies
- Colorectal Cancer24 studies
- Cardiovascular Disease22 studies
- Endometrial Cancer20 studies
- Acute Myeloid Leukemia20 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.